In relation to discussion re potential partners... I'd say a lot is going on behind the scenes (see points below from past announcements). Then read the last point taken from new website. PYC are just warming up.
Phylogica/Isogenica Collaboration:
* Phylogica scientists are now confident that using the display technology will ensure accelerated screening of the company’s vast Phylomer libraries to meet demand from potential pharmaceutical partners.
* Isogenica’s technology is well established within the industry and the company has relationships with many of Phylogica’s current and prospective pharmaceutical partners.
* Dr Watt said this combination of the Phylomer libraries with Isogenica’s CIS display technology represents a value-adding expansion of Phylogica’s drug discovery platform and could open up new partnership opportunities.
* “The two companies are exploring a broader alliance to exploit the unique commercial potential of their combined technologies,” he said.
* Isogenica CEO Dr Kevin Matthews said: “The pharmaceutical industry is constantly exploring new molecular structures that could lead to significant new medical treatments. The broad structural diversity of Phylogica’s Phylomer libraries, as a starting point, combined with the ability to rapidly generate trillions of Phylomer variants, fast-tracks molecular evolution and could generate improved lead candidates in a much shorter time frame.”
...........................
On Pepscan:
Phylogica’s CEO, Dr Paul Watt, said: "We are excited to be working with Pepscan, which has world-class technology for improving the activity and stability of therapeutic peptides. We strongly believe that the combination of Pepscan’s CLIPS technology with our potent Phylomer peptides will further enhance our ability to generate breakthrough drug candidates against difficult-to-treat diseases.”
.....................................
On PYCAG5:
Phylogica is now pursuing partnering opportunities with major pharmaceutical and biotech companies for further development of its lead candidate, PYCAG5, and the Company’s other neuroprotective Phylomers. This out-licensing strategy is consistent with Phylogica’s discovery alliance focused business model.
and....
On new site:
New drug class and market
Phylomer® libraries contain billions of unique peptide drug leads that represent a new drug class known as Phylomer® peptides. These peptides form part of the rapidly growing biologic market. This US$120 billion market is expected to constitute half of all drugs by 2015.
PYC Price at posting:
5.1¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)